This study seeks to determine the safety, biological activity, and effect of SCH 58500 in the local-regional gene therapy of primary and metastatic malignant tumors of the liver which suffer p53 alteration. The study design consists of an open-label, nonrandomized, single-dose, dose-escalation Phase I trial. SCH 58500 will be administered by hepatic artery infusion to patients with primary (hepatocellular cancer) or metastatic (colorectal cancer) tumors of the liver.
Showing the most recent 10 out of 675 publications